Table 1 Completed clinical trials using TILs-based immunotherapy
Cancer type/conditions | Study title | Study type/phase | Intervention/treatment | Status | NCT number |
|---|---|---|---|---|---|
Metastatic ovarian cancer | TIL therapy in combination with checkpoint inhibitors for metastatic ovarian cancer | Interventional; Phase I and II | TILs in combination with checkpoint inhibitors | Completed | NCT03287674 |
Metastatic melanoma | Peginterferon and TIL therapy for metastatic melanoma | Interventional; Phase I and II | TILs infusion including lymphodepleting chemotherapy and interleukin-2 | Completed | NCT02379195 |
Metastatic melanoma | Vemurafenib and TIL therapy for metastatic melanoma | Interventional; open-label Phase I and II | T cell Therapy in combination with Vemurafenib | Completed | NCT02354690 |
Multiple myeloma | Trial of activated marrow infiltrating lymphocytes alone or in conjunction with an allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine in the autologous transplant setting in multiple myeloma | Interventional; Phase II | Activated marrow infiltrating lymphocytes alone or in conjunction with an allogeneic GM-CSF vaccine | Completed | NCT01045460 |
Multiple myeloma and plasma cell neoplasm | Activated white blood cells with ASCT for newly diagnosed multiple myeloma | Interventional; Phase I and II | Activated marrow infiltrating lymphocytes | Completed | NCT00566098 |
Melanoma | Phase II study of short-term cultured anti-tumor autologous lymphocytes after lymphocyte-depleting chemotherapy in metastatic melanoma | Interventional; Phase II | Cultured anti-tumor autologous lymphocytes following a lymphocyte depletion | Completed | NCT00513604 |
Melanoma | Phase II study of metastatic melanoma with lymphodepleting conditioning and infusion of anti-MART-1 F5 TCR-gene-engineered lymphocytes | Interventional; Phase II | Lymphodepletion followed by infusion of anti-MART-1 F5 TCR-gene engineered lymphocytes | Completed | NCT00509288 |
Melanoma neoplasm metastasis | Lymphocyte re-infusion during immune suppression to treat metastatic melanoma | Interventional; Phase II | Lymphocyte re-infusion during immune suppression | Completed | NCT00001832 |
